Epcoritamab with R-CHOP for Aggressive Non-Hodgkin Lymphoma
This study is looking at a new way to treat aggressive B-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL). It combines a drug called epcoritamab with a standard chemotherapy treatment called R-CHOP (Rituximab, Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisolone). Researchers want to see how safe this combination is and how well it works to fight the cancer. They will also be watching for a side effect called Cytokine Release Syndrome (CRS). You might be able to join if you are an adult with newly diagnosed aggressive B-cell lymphoma that is CD20-positive. The study plans to enroll 20 participants.
- Study design
- This is an open-label study, meaning you and your doctors will know which treatments you are receiving. It is designed to see the safety and effectiveness of the treatment in about 20 participants.
- What's involved
- You will receive epcoritamab, R-CHOP chemotherapy, and dexamethasone, given orally, intravenously, and subcutaneously. You will also have blood work and PET imaging.
- Compensation
- Not stated in the trial record.
- Follow-up
- You will be followed at Week 8 and every 3 months for up to one year, or until your condition improves, stabilizes, or you start a new therapy.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma
At a glance
Conditions
Where it's being run
2 sites across 1 statesStudy leadership
- Carrie Ho, MD · PRINCIPAL_INVESTIGATOR · University of California, San Francisco
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
What this trial measures
- Cytokine Release Syndrome (CRS) RateUp to day 42
The cytokine release syndrome (CRS) rate is defined as the incidence of CRS of any grade during Cycle 2, graded according to the American Society for Transplantation and Cellular Therapy (ASTCT) consensus criteria. The proportion and corresponding 95% confidence interval will be reported.